NCT04748744

Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 400 (actual)
• Sponsor: University Hospital of Patras · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Butyrylcholinesterase (BChE) is an α-glycoprotein synthesized in the liver. BchE's serum level decreases in many clinical conditions such as acute and chronic liver damage, inflammation, injury and infections, and malnutrition. The Investigators prospectively evaluate patients undergoing elective procedures for colorectal diseases. Blood samples are collected preoperatively (at day 0), post-operatively in the recovery room (day 1), and on the subsequent four days (days 2, 3, 4, and 5) for assessment of BChE, C-reactive protein, and white blood cell concentrations. The same surgical team operates all patients and is blinded to the study. Patients are monitored for post-operative infection by using standard laboratory and clinical methods. If surgical site infection (SSI) is suspected the wound is swabbed and empirical antibiotics are started. The aim of the current trial is to study whether BChE is a reliable marker for the presence of SSI in patients undergoing colorectal surgery.

Detailed description

Butyrylcholinesterase (BChE or BuChE) is a cholinesterase enzyme that is very similar to acetylcholinesterase (AChE). However, though the role and function of AChE in the human body are widely studied and known, BChE is usually referred to as an 'orphan enzyme' because its specific physiological role is still under question. Lastly, it has been found, however, that BChE has more specific functions than it was previously believed and acetylcholine (ACh), which will be further analyzed, can affect the immune system and is associated with inflammation-related events. Butyrylcholinesterase is an enzyme that for several years was not considered to have a specific physiological role but lately, it has been observed that plays an important role in inflammation as acetylcholine is a major player of the 'cholinergic anti-inflammatory pathway' inhibiting inflammation. It has been proved that BChE activity can be affected by several diseases. Low-grade inflammation is associated with an increase of its levels whereas a reduction is observed when systemic inflammation is present. However, future research is needed in order to be widely used in clinical practice as a biomarker for several pathological conditions involving inflammation. Therefore, the aim of this study is to present information about butyrylcholinesterase, its function, and its role in the human body, highlighting its association with inflammation analyzing past studies about this subject. The Investigators prospectively evaluate patients undergoing elective procedures for colorectal diseases. Blood samples are collected preoperatively (at day 0), post-operatively in the recovery room (day 1), and on the subsequent four days (days 2, 3, 4, and 5) for assessment of BChE, C-reactive protein, and white blood cell concentrations. The same surgical team operates all patients and is blinded to the study. Patients are monitored for post-operative infection by using standard laboratory and clinical methods. If surgical site infection (SSI) is suspected the wound is swabbed and empirical antibiotics are started. The aim of the current trial is to study whether BChE is a reliable marker for the presence of SSI in patients undergoing colorectal surgery.

Conditions

• Colorectal Disorders
• Colorectal Neoplasms

Interventions

Type	Name	Description
COMBINATION_PRODUCT	Butyrylcholinesterase	Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases

Timeline

• Start date: 2019-11-06
• Primary completion: 2023-05-01
• Completion: 2023-05-01
• First posted: 2021-02-10
• Last updated: 2023-06-15

Locations

1 site across 1 country: Greece

Regulatory

• FDA-regulated drug study